RT Journal Article
SR Electronic
A1 Mayfield, Eleanor
T1 MATRIX
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 5
SP 9
OP 10
DO 10.1177/1559897715583814
UL http://mdc.sagepub.com/content/15/5/9.abstract
AB The MATRIX trial in patients with acute coronary syndrome who were being managed invasively found that transradial access reduced the occurrence of a net composite end point that included bleeding and efficacy, as well as death and major bleeding, when compared with transfemoral access. Bivalirudin did not reduce the occurrence of either of the co-primary composite end points, but exploratory analyses found that death and bleeding were reduced with bivalirudin when compared with unfractionated heparin.